Search

Copyright of Der Internist is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Transcatheter Treatment of Severe Tricuspid Regurgitation Abstract. Severe tricuspid regurgitation can lead to increased morbidity and mortality due to clinical symptoms and impairment of organ function. With the emergence of new interventional treatment options, the once neglected tricuspid valve is receiving increased attention. The following article intends to provide an overview of the causes, diagnostic modalities, and therapeutic options of severe tricuspid regurgitation.

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death in the world. The majority of HCCs develops on the basis of a chronic liver disease. This often complicates diagnosis and therapy. Non-invasive diagnostic criteria are based on dynamic imaging techniques and the serum level of AFP (alpha-fetoprotein). When evaluating HCC patients for therapy, besides tumor burden and localisation, the therapeutic evaluation must also consider the general condition of the patient and his/her liver function. For this purpose, the BCLC algorithm of the Barcelona Clinic for Liver Disease has proven helpful. Only one-third of the patients can be cured by resection, transplantation or local tumour ablation. In locally advanced cases transarterial procedures including transarterial chemoembolisation and radioembolisation are applied. HCC is a chemo-resistant tumour and chemotherapy is not accepted as standard of care in HCC. Sorafenib is the first systemic treatment with proven efficacy approved for the treatment of advanced and metastatic HCC. Interdisciplinary management of HCC patients is essential in order to provide every patient with the optimal therapy at his specific stage of disease.

A New Tool for Expertising Nursing-Care Need? Since the introduction of the long-term care insurance in April 1995 criticism of the mode of expertise used to assign a particular nursing status to a patient has not ceased. Nursing status is required to receive monetary benefit from the long-term care insurance. According to the code of social law (SGB XI) nursing status is based on the total amount of time in minutes a care-needing person requires help to perform certain activities of daily living (ADL). This time-based classification is the bone of contention. As the currently used classification instrument has not been validated and is not reliable, it has been the aim of the present study to introduce a more objective mode of expertise. In our study we used the Barthel-Index as an instrument that allows to assign nursing status to a person in agreement with the person's respective ability to fulfil ADL. In a prospective study 252 patients were examined by the raters of the MDK Bavaria (Medical Service of Health Insurance) according to the SGB XI and the Barthel-Index. On the basis of the Barthel-Index and a certain discriminatory function more than 86% of the patients were assigned the same nursing status as with the normally used mode of expertise. Most of the differing results were borderline cases between two levels of nursing status. The new mode of expertising results in a more balanced distribution of different levels of nursing status. Therefore, the Barthel-Index in combination with the discriminatory function is as effective as the normally used mode of expertising. It is a valid and reliable instrument which could well replace the mode of expertising used so far.